Target intelligence / Profile preview

Vibrio cholerae O1 whole-cell antigens (V. cholerae O1 antigens)

Target
V. cholerae O1 antigens
Molecular classification
Bacterial antigen, Lipopolysaccharide, Whole-cell antigen
01

Overview

Vibrio cholerae O1 whole-cell antigens are the primary immunogenic components utilized in the formulation of oral cholera vaccines (OCVs) to provide protection against the bacterium responsible for epidemic cholera (World Health Organization, 2023). These antigens typically comprise heat- or formalin-inactivated whole cells of the V. cholerae O1 serogroup, encompassing both the Ogawa and Inaba serotypes and the El Tor and Classical biotypes (CDC, 2022). The most critical component is the O1-specific lipopolysaccharide (LPS), which serves as the major target for the host's immune system to generate protective vibriocidal antibodies and mucosal secretory IgA (Levine et al., 2017, PubMed). By stimulating a robust immune response against these surface structures, the vaccines prevent the bacteria from colonizing the intestinal mucosa, thereby inhibiting the progression of the disease and the subsequent release of cholera toxin (Sack et al., 2004, The Lancet). These antigens are essential for both reactive outbreak control and long-term preventative strategies in cholera-endemic areas. In addition to LPS, other surface proteins and, in some formulations, the cholera toxin B-subunit (CTB) contribute to the overall efficacy of the immune response (Wierzba et al., 2015). The use of whole-cell antigens ensures a broad spectrum of epitopes are presented to the immune system, mimicking a natural infection without the risk of disease. Clinical monitoring of the response to these antigens is primarily conducted through the measurement of serum vibriocidal antibody titers, which correlate with protection levels in vaccinated individuals.

Other names
Vibrio cholerae O1 lipopolysaccharideV. cholerae O1 surface antigensO1 antigenKilled whole-cell Vibrio cholerae O1
02

Mechanism of action

Induction of mucosal and systemic immunity, primarily through the production of vibriocidal antibodies and secretory IgA (sIgA) targeting the O1 lipopolysaccharide, which prevents bacterial attachment and colonization in the small intestine.

03

Biological functions

Immune response inductionBacterial colonizationPathogenesis
04

Disease associations

CholeraInfection
05

Safety considerations

Gastrointestinal distressAbdominal painNauseaDiarrheaShort-term immunity in children
06

Interacting drugs

Dukoral

4 more in the full profile.

07

Biomarkers

Vibriocidal antibody titerAnti-LPS IgAAnti-LPS IgG

Beyond the preview

Go deeper on Vibrio cholerae O1 whole-cell antigens (V. cholerae O1 antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibrio cholerae O1 whole-cell antigens (V. cholerae O1 antigens).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call